A5020602973- Hematopoietic Stem Cell Transplantation
- Acute Lymphoblastic Leukemia research
- Acute Myeloid Leukemia Research
- Mesenchymal stem cell research
- Chronic Myeloid Leukemia Treatments
- Chronic Lymphocytic Leukemia Research
- Biomedical Ethics and Regulation
- Renal Transplantation Outcomes and Treatments
- Polyomavirus and related diseases
- CAR-T cell therapy research
- T-cell and B-cell Immunology
- Lymphoma Diagnosis and Treatment
- Organ Transplantation Techniques and Outcomes
- Pluripotent Stem Cells Research
- Eosinophilic Disorders and Syndromes
- Immunodeficiency and Autoimmune Disorders
- Multiple Myeloma Research and Treatments
- Immunotherapy and Immune Responses
- Clinical practice guidelines implementation
- Transplantation: Methods and Outcomes
- Neutropenia and Cancer Infections
- Liver physiology and pathology
- Tissue Engineering and Regenerative Medicine
- Immune Cell Function and Interaction
- Health Systems, Economic Evaluations, Quality of Life
University Hospital of Basel
2016-2025
University of Basel
2009-2023
Josep Carreras Leukaemia Research Institute
2012
Universitat de Barcelona
2012
European Society for Blood and Marrow Transplantation
2011
Radboud University Nijmegen
2011
Leiden University
1996-2011
University Hospital Leipzig
2011
Swiss Red Cross
2010
GTx (United States)
2009
Hematopoietic stem cell transplantation (HSCT) requires significant infrastructure. Little is known about HSCT use and the factors associated with it on a global level.To determine current of to assess differences in its application explore associations macroeconomic transplant rates level.Retrospective survey study patients receiving allogeneic autologous HSCTs for 2006 collected by 1327 centers 71 participating countries Worldwide Network Blood Marrow Transplantation. The regional areas...
A record number of 40 829 hematopoietic stem cell transplantation (HSCT) in 36 469 patients (15 765 allogeneic (43%), 20 704 autologous (57%)) were reported by 656 centers 47 countries to the 2014 survey. Trends include: continued growth transplant activity, more so Eastern European than west; a increase use haploidentical family donors (by 25%) and slower for unrelated donor HSCT. The cord blood as source has decreased again 2014. Main indications HSCT leukemias: 11 853 (33%; 96%...
Abstract BACKGROUND: It was investigated whether the European Group for Blood and Marrow Transplantation risk score, previously established chronic myeloid leukemia, could be used to predict outcome after allogeneic hematopoietic stem cell transplantation (HSCT) hematological disease in general. METHODS: Age of patient, stage, time interval from diagnosis transplant, donor type, donor‐recipient sex combination were establish a score 0 7 points. Its validity tested 56,505 patients, 33,113...
Numbers of Hematopoietic cell transplantation (HCT) in Europe and collaborating countries continues to rise with 48,512 HCT 43,581 patients, comprising 19,798 (41%) allogeneic 28,714 (59%) autologous, reported by 700 centers 51 during 2019. Main indications were myeloid malignancies 10,764 (25%), lymphoid 27,895 (64%), nonmalignant disorders 3173 (7%). A marked growth CAR-T cellular therapies from 151 2017 1134 patients 2019 is observed. This year's analyses focus on changes over 30 years....
Information on incidence, and factors associated with mortality is a prerequisite to improve outcome after hematopoietic stem cell transplantation (HSCT). Therefore, 55′668 deaths in 114′491 patients HSCT (83.7% allogeneic) for leukemia were investigated landmark analysis causes of death at day 30 (very early), 100 (early), 1 year (intermediate) 5 years (late). Mortality from all decreased cohort (1980–2001) 2 (2002–2015) post-transplant phases autologous HSCT. After allogeneic HSCT,...
A record number of 39 209 HSCT in 34 809 patients (14 950 allogeneic (43%) and 19 859 autologous (57%)) were reported by 658 centers 48 countries to the 2013 survey. Trends include: more growth than HSCT, increasing use sibling unrelated donors a pronounced increase haploidentical family when compared with cord blood for those without matched related or donor. Main indications leukemias, 11 190 (32%; 96% allogeneic); lymphoid neoplasias, 958 (57%; 11% solid tumors, 1543 (4%; 4% nonmalignant...
Abstract Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants performed in Europe associated countries continues to rise with 47,468 HCT 42,901 patients [19,630 allogeneic (41%) 27,838 autologous (59%)] reported by 701 centers 50 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid 27,318 (64%; 20% solid tumors 1625 (4%; 2.9% nonmalignant 3063 (7%; 81% allogeneic). This...
The Worldwide Network of Blood and Marrow Transplantation (WBMT) pursues the mission promoting hematopoietic cell transplantation (HCT) for instance by evaluating activities through member societies, national registries individual centers. In 2016, 82,718 first HCT were reported 1,662 teams in 86 195 World Health Organization states representing a global increase 6.2% autologous 7.0% allogeneic bringing total to 1,298,897 procedures. Assuming frequency 84,000/year, 1.5 million performed 2019...
Hematopoietic cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number transplants done in Europe associated countries continues to rise with 45,418 HCT 41,100 patients [(17,155 allogeneic (42%) 23,945 autologous (58%)] reported by 683 centers 50 2017. Main indications were myeloid malignancies 10,147 (25%; 96% allogeneic), lymphoid 26,488 (64%; 19% solid tumors 1,607 (3.9%; 2% nonmalignant 2,667 (7%; 81% allogeneic). Trends donor...
Abstract In 2021, 47,412 HCT (19,806 (42%) allogeneic and 27,606 (58%) autologous) in 43,109 patients were reported by 694 European centers. 3494 received advanced cellular therapies, 2524 of which CAR-T treatments, an additional 3245 DLI. Changes compared to the previous year treatment (+35%), +5.4%, autologous +3.9%, more pronounced non-malignant disorders. Main indications for myeloid malignancies 10,745 (58%), lymphoid 5127 (28%) disorders 2501 (13%). 22,129 (90%) solid tumors 1635 (7%)....
Abstract In 2022, 46,143 HCT (19,011 (41.2%) allogeneic and 27,132 (58.8%) autologous) in 41,854 patients were reported by 689 European centers. 4329 received advanced cellular therapies, 3205 of which CAR-T. An additional 2854 DLI. Changes compared to the previous year an increase CAR-T treatments (+27%) decrease (−4.0%) autologous (−1.7%). Main indications for myeloid malignancies (10,433; 58.4%), lymphoid (4,674; 26.2%) non-malignant disorders (2572; 14.4%). lymphomas (7897; 32.9%), PCD...
The risk for donors of allogeneic hematopoietic stem cells transplants is generally considered negligible. Scattered reports severe complications and a recent controversy on malignancies after granulocyte colony-stimulating factor administration have challenged this opinion.Three hundred thirty-eight transplant teams from 35 primarily European countries were asked to report numbers fatalities, adverse events hematologic occurring among their cell donors.Two sixty-two the 338 (77.5%)...
In all, 661 of 680 centers in 48 countries reported 37 818 hematopoietic SCT (HSCT) 33 678 patients (14 165 allogeneic (42%), 19 513 autologous (58%)) the 2012 survey. Main indications were leukemias, 10 641 (32%; 95% allogeneic); lymphoid neoplasias, 336 (57%; 11% solid tumors, 1630 (5%; 3% and nonmalignant disorders, 1953 (6%; 90% allogeneic). There more unrelated donors than HLA-identical sibling (54% versus 38% (8% being mismatched related donor HSCT)). Cord blood was almost exclusive...
Hematopoietic cell transplantation (HCT) is an established procedure for acquired and congenital disorders of the hematopoietic system. In 2016, there was a tendency continued activity in this field with 43,636 HCT 39,313 patients [16,507 allogeneic (42%), 22,806 autologous (58%)] reported by 679 centers 49 countries 2016. The main indications were myeloid malignancies 9547 (24%; 96% allogeneic), lymphoid 25,618 (65%; 20% solid tumors 1516 (4%; 2% non-malignant 2459 (6%; 85% allogeneic)....
In all, 651 from 680 centers in 48 countries reported 35 660 hematopoietic SCT (HSCT) 32 075 patients (13 470 allogeneic (42%), 18 605 autologous (58%)) to the 2011 survey. Main indications were: leukemias; 10 113 (32%; 94% allogeneic); lymphoid neoplasias; non-Hodgkin's lymphoma, Hodgkin's plasma cell disorders; 433 (57%; 12% solid tumours; 1573 (5%; 5% and non-malignant 1830 (6%; 92% allogeneic). There were more unrelated donors than HLA identical sibling (54% versus 39%); proportion of...
Fifty-five years after publication of the first hematopoietic stem cell transplantation this technique has become an accepted treatment option for defined hematologic and non-hematologic disorders. There is considerable interest in understanding differences its use trends on a global level macro-economic factors associated with these differences. Data numbers transplants performed 3-year period 2006–2008 were obtained from Worldwide Network Blood Marrow Transplantation member registries...
Abstract In 2020, 45,364 HCT in 41,016 patients, 18,796 (41%) allogeneic and 26,568 (59%) autologous 690 centers were reported. Changes observed as follows: total number of −6.5%, −5.1%, −7.5%, more pronounced non-malignant disorders for autoimmune disease HCT. Main indications myeloid malignancies 10,441 (25%), lymphoid 26,120 (64%) 2532 (6%). A continued growth CAR-T cellular therapies to 1874 (+65%) patients 2020 was observed. HCT, the use haploidentical donors increased while unrelated...